60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▲(200.00% Upside)
Action:ReiteratedDate:03/31/26
The score is held down mainly by weak financial performance (large ongoing losses and cash burn despite improving revenue) and bearish technical trends (price below key moving averages with negative MACD). Valuation provides limited support due to negative earnings, while corporate events are slightly positive on regained Nasdaq compliance but tempered by prior delisting risk and potential dilution signals.
Positive Factors
Sustained Revenue Growth
Material multi-year revenue growth demonstrates expanding commercial traction and product uptake. A rising revenue base provides a firmer foundation to absorb fixed costs, supports future scale, and de-risks the development-to-commercial transition if growth continues over the next 2–6 months.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow signals ongoing funding needs and constrains reinvestment. Persistent cash burn pressures liquidity, forces reliance on external financing, and increases dilution risk if internal cash generation does not improve within the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Material multi-year revenue growth demonstrates expanding commercial traction and product uptake. A rising revenue base provides a firmer foundation to absorb fixed costs, supports future scale, and de-risks the development-to-commercial transition if growth continues over the next 2–6 months.
Read all positive factors
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.64M
Dividend YieldN/A
Average Volume (3M)199.18K
Price to Earnings (P/E)―
Beta (1Y)2.46
Revenue Growth192.72%
EPS Growth83.61%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.91
Shares Outstanding2,636,788
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.28
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.00Price Target Upside4700.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$2.00M
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevent...
How the Company Makes Money
Revenue is generated primarily through the commercialization and sale of its pharmaceutical products. This includes sales to distributors, healthcare providers, and/or government or institutional buyers in markets where the company has regulatory ...
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01M | 607.57K | 253.57K | 223.21K | 1.16M |
| Gross Profit | 223.78K | 222.81K | -220.98K | -209.16K | 309.60K |
| EBITDA | -7.28M | -7.88M | -1.43M | -2.11M | -1.01M |
| Net Income | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M |
Balance Sheet | |||||
| Total Assets | 5.37M | 5.76M | 7.78M | 1.30M | 1.39M |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 3.39M | 2.14M | 264.87K | 115.40K |
| Total Debt | 152.78K | 155.89K | 172.67K | 22.42M | 18.80M |
| Total Liabilities | 1.99M | 1.80M | 2.99M | 25.45M | 19.55M |
| Stockholders Equity | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M |
Cash Flow | |||||
| Free Cash Flow | -7.07M | -5.83M | -4.66M | -1.07M | -684.50K |
| Operating Cash Flow | -6.85M | -5.65M | -4.54M | -1.01M | -649.11K |
| Investing Cash Flow | 254.92K | -1.89M | -115.89K | -60.13K | -35.39K |
| Financing Cash Flow | 6.44M | 7.05M | 6.47M | 1.22M | 611.23K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
Negative
0.50
Price Trends
2.69
Negative
2.99
Negative
4.55
Negative
Market Momentum
-0.23
Negative
42.03
Neutral
58.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 1.83, below the 50-day MA of 2.69, and below the 200-day MA of 4.55, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 42.03 is Neutral, neither overbought nor oversold. The STOCH value of 58.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.
60 Degrees Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $4.64M | -0.18 | -212.63% | ― | 192.72% | 83.61% | |
| ― | $2.61M | -0.17 | -168.95% | ― | ― | 90.27% | |
40 Underperform | $185.00M | -0.36 | -2323.94% | ― | ― | 52.39% | |
| ― | $755.29K | -1.82 | -263.57% | ― | -34.58% | 96.41% |
* Healthcare Sector Average
SXTP
60 Degrees Pharmaceuticals, Inc.
1.76
-11.28
-86.50%
OGEN
Oragenics
0.60
-5.08
-89.39%
KALA
KALA BIO
0.20
-3.29
-94.18%
KTTA
Pasithea Therapeutics Corp
0.70
-0.48
-40.68%
SPRC
SciSparc Ltd.
3.15
-53.98
-94.49%
ONCO
Onconetix
1.09
-28.49
-96.32%
60 Degrees Pharmaceuticals, Inc. Corporate Events
Regulatory Filings and ComplianceStock Split
60 Degrees Updates Affiliate Share Ownership Disclosure Error
Neutral
Mar 20, 2026
On March 20, 2026, 60 Degrees Pharmaceuticals, Inc. reported that it had miscalculated the number of shares of common stock beneficially owned by a company affiliate in a prospectus supplement dated March 13, 2026. The affiliate’s holdings w...
Private Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering
Neutral
Mar 13, 2026
On March 13, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion covering the shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright Co., LLC, originally established under a Sep...
Private Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Updates Opinion for ATM Program
Positive
Mar 12, 2026
On March 12, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion of counsel covering shares of common stock issued and sold under its at-the-market equity offering program established under a September 5, 2025 sales agreement wit...
Delistings and Listing ChangesRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status
Positive
Feb 12, 2026
On January 20, 2026, 60 Degrees Pharmaceuticals received notice from Nasdaq that its common stock and warrants were subject to delisting for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, prompting the...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting Appeal
Negative
Jan 23, 2026
On January 20, 2026, 60 Degrees Pharmaceuticals, Inc. received a written notice from the Nasdaq Listing Qualifications Department stating that Nasdaq staff had determined to delist the company’s common stock and warrants from the Nasdaq Capi...
Delistings and Listing ChangesShareholder MeetingsStock Split
60 Degrees Pharmaceuticals Implements One-for-Four Reverse Split
Neutral
Jan 21, 2026
On October 8, 2025, stockholders of 60 Degrees Pharmaceuticals, Inc., following a recommendation from the board, approved an amendment to implement a one-for-four reverse stock split of the company’s common stock, which became effective at 1...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
60 Degrees Pharma outlines growth strategy in investor webinar
Positive
Jan 8, 2026
On January 8, 2026, 60 Degrees Pharmaceuticals made available an investor presentation tied to a RedChip-hosted webinar, providing updated information on its clinical development timelines and regulatory strategy. The materials highlighted growing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.